Coherus Oncology, Inc.

Healthcare · Biotechnology · United States

Last price 0.8301 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 128.25M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibo...